Pipeline Progressing News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share:
Interim Analysis of Second Confirmatory Phase 3 Study in Fibromyalgia 
Expected in Third Quarter 2021
Deep Pipeline Progressing with Three Central Nervous System 
(CNS) Programs Expected to Enter Phase 2 Trials This Year
At March 31, 2021, Cash and Cash Equivalents Totaled Approximately $164 Million
CHATHAM, N.J., May 10, 2021 (GLOBE NEWSWIRE) Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2021 and provided an overview of recent operational highlights.
Tonix possesses a deep pipeline of high-value programs ranging from preclinical to mid-Phase 3 development, with three CNS programs poised to enter Phase 2 trials this year, said Seth Lederman, M.D., President and Chief Executive Officer. Our strategy is to in-license, acquire or internally invent high impact therapeutic programs which we can valid ....

United States , Rydyznski Moderbacher , Jessica Morris , Seth Lederman , Olipriya Das , Le Bert , Peter Vozzo , Us National Cancer Institute , Tonix Pharmaceuticals , French National Institute Of Health , Harvard Medical School Teaching Hospital Massachusetts , Drug Administration , Exchange Commission , Tonix Pharmaceuticals Holding Corp , Oyagen Inc , Announced Positive Efficacy Data , Animal Studies , Second Confirmatory Phase , Third Quarter , Pipeline Progressing , Three Central Nervous System , Programs Expected , Center Phase , Cash Equivalents Totaled Approximately , Pharmaceuticals Holding , Chief Executive ,